Category Archives: Biochemistry

Expert In Biochemistry Dr. Yesu Addepalli Works On A Micro Level To Bring Macro Changes To The Development Of Novel Therapeutics – Tech Times

(Photo : Dr. Yesu Addepalli)

In addition to studying the complex chemical and physical properties of living things, dissecting their cellular structures, and understanding how they interact with different compounds, biochemists play a key role in providing the foundational knowledge and science used to develop health treatments and medical drugs.

Dr. Yesu Addepalli is a renowned expert in the field of biochemistry, having played a critical role in the drug discovery and synthesis of biologically active small molecules. This work has the potential to be revolutionary for the biopharmaceutical industry, as our society battles a wide variety of viruses and diseases. The PHD holder has a unique and valuable perspective thanks to his multifaceted education in organic chemistry, medicinal chemistry, and chemical biology.

Dr. Addepalli was instrumental in the development of antiparasitic drugs for leishmaniasis and trypanosomiasis. When asked about his methods, he explains: "My efforts were geared towards the utilization of chemical derivatization and forward genetic approaches to study a class of compounds that selectively test derivatives for selective activity on Leishmania tubulin and trypanosomatids. [From there, I] assessed their stability, solubility, cell permeability, and in vivo PK properties. [I] performed proof-of-concept testing in the mouse model of leishmaniasis and used a modular synthetic strategy, and Cryo-EM techniques to discover the binding site of a class of pyrimidinone derivatives. [Finally I] optimized promising agents for oral administration and performed dose response testing in animal models."

This work, at the University of Texas Southwestern Medical Center's Ready laboratory, will allow the development of compounds with a high therapeutic index for the treatment of trypanosomatid infections, based on the identification of molecules that inhibit targeting parasite tubulin polymerization. The newly found understanding of the drug target and mechanism brings promise for the treatment of these arthropod-borne diseases.

Dr. Yesu Addepalli earned his Master of Science degree in organic chemistry from the Government College (Autonomous), Rajahmundry in India before going on to complete his doctoral degree in organic chemistry under the guidance of Research Advisor Prof. Yun He at Chongqing University in China. Most recently, he has been working in a postdoctoral position with esteemed-researcher Professor Joseph Ready at the University of Texas Southwestern Medical Center, which provides him with both the tools and community to evolve and deepen his studies.

"I find bioactive small molecules to be fascinating. The design, synthesis, purification, and characterization of viruses and [their] treatment drugs are a wonder to behold, study, and develop." Dr. Addepalli shares, "Some people find beauty in the world around [them], but I see beauty in the microscopic world of viruses and find great pleasure in being instrumental in halting the spread of viruses through synthesizing biopharmaceuticals."

Although the work is rewarding,Dr. Yesu Addepalli recognizes that it is also a great responsibility, as each challenge is fundamentally a battle between life and death. He is grateful for the diversity of knowledge and skills that his team holds, as it brings them closer to streamlined bioactive molecule development. He is also currently collaborating with biologists at UT Southwestern, and elsewhere, using high-throughput screening strategies to discover small molecules with promising biological activity in an effort to identify compounds and molecules that will push the boundaries of genetic studies. The characterization of biologically active small molecules is a breakthrough for the development of novel therapeutics for neurodegenerative and infectious diseases, as well as for cancer.

Dr. Addepalli's esteemed work has been featured in a variety of reputable publications, and he also has a US patent for his team's work specifically with novel antiparasitic compounds and methods. He is an active member of the American Society for Biochemistry and Molecular Biology, as well as the Society for Immunotherapy of Cancer. In his free time, he also enjoys reviewing for publications such as Tetrahedron and Heterocyclic Chemistry.

His work revolves around molecules and compounds that are far too small to see with the naked eye, but the impact of his work has a very large scope. As our society has recently been reminded of the threat that these microscopic elements can bring, the work of Dr. Addepalli is perhaps more important than ever before. Gaining a stronger understanding of how these microscopic molecules create disease will help us to understand how to reverse and treat the disease. As they say, knowledge is power.

2022 TECHTIMES.com All rights reserved. Do not reproduce without permission.

Tags:

Excerpt from:
Expert In Biochemistry Dr. Yesu Addepalli Works On A Micro Level To Bring Macro Changes To The Development Of Novel Therapeutics - Tech Times

New Program Honors Effective Teachers and Rekindles Joy in Education | College of Human Medicine | Michigan State University – Michigan State…

August 30, 2022

In the midst of the pandemic, with teaching and many other parts of life disrupted, Randi Stanulis decided it was time to rekindle the joy that College of Human Medicine faculty members find in helping students grow and succeed.

I know that coming out of the pandemic, we found that many of us were experiencing burnout and people feeling we were stretched too thin, said Stanulis, PhD, assistant dean for faculty development and director of the colleges Office of Medical Education Research and Development (OMERAD). It made me think we needed to do something about it.

Thus, a year ago was born Finding Joy in Teaching, an honorific program based on the belief that the best teachers love what they do. Research shows that the most effective teachers not only like what they do, but are flexible and focused on student growth, Stanulis said.

There are a lot of people who say, I teach biochemistry, she said. I say, No, you teach students about biochemistry. That shift is significant.

A year ago, College of Human Medicine department chairs and directors nominated faculty members known for their effective teaching skills and enthusiasm. Stanulis then led the recording of a series of 10 short audio presentations offering the honorees perspectives and suggestions on the joy of teaching. The episodes were posted online and celebrated at the inaugural Joy in Teaching reception, funded in part by the Dr. Ruth Allen Endowment in OMERAD.

The idea for this movement is to elevate a culture where teaching effectiveness is valued and where peers can see what others are doing and be inspired by that, Stanulis said, adding that it really raised awareness to another level that teaching is joyful, is recognized, and is valued at the College of Human Medicine.

While research is an important part of the colleges mission, skillful teaching is equally essential, she said.

In October, department chairs and directors will nominate a second cohort of faculty members to be recognized for their teaching excellence in Finding Joy in Teaching. Those chosen will add their perspectives to the audio series collection and will be honored in the spring. For most, it is clear through listening to their audio episodes, teaching is its own reward.

For 18 years, Stanulis was a professor in MSUs Department of Teacher Education in the College of Education before becoming director of OMERAD.

I enjoy the energy that comes from students when they are actively involved, she said. I enjoy their curiosity. I enjoy seeing them light up as they learn.

Continue reading here:
New Program Honors Effective Teachers and Rekindles Joy in Education | College of Human Medicine | Michigan State University - Michigan State...

Carleton University and Turnstone Biologics Extend partnership for Research and Training in Biosciences – Carleton Newsroom

Carleton University today announced the extension of its partnership with Turnstone Biologics (Turnstone), a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumours. The partnership, renewed for a second term, further supports Carletons growing biosciences programs and the development of scientific talent, and augments the universitys expertise in novel oncology research.

This is an opportune time to extend our partnership with Turnstone as we prepare to launch our Life Sciences 2030 Plan, said Maria DeRosa, PhD, Dean of Science and Professor in the Department of Chemistry and the Institute of Biochemistry, Carleton University. Our vision of positioning Carleton as the premier Canadian post-secondary institution for training, talent development and research in the life sciences sector is significantly enhanced through our innovative and productive relationship with Turnstone.

Since 2019, Turnstone has conducted internal development work and sponsored research at Carleton University. The research being undertaken at Carleton includes generating new insights into how cancer therapies regulate immune cells and their effects on new candidate treatments, and how viruses and environmental toxins contribute to the development of chronic diseases. Additionally, representatives of Turnstone have mentored students and participated in life sciences events on campus.

Carleton University offers a wonderful and vibrant academic community. The partnership with Carleton allows us to interact with a variety of excellent researchers and promising students to create opportunities to collaborate, foster scientific ideas and invest in the brilliant minds of the future, said David Stojdl, PhD, Scientific Co-Founder, Senior Vice President and Senior Scientific Fellow, Turnstone Biologics.

The extension of the partnership enables Turnstone to continue engaging graduate students and to provide them with support to conduct research in the areas of immunology, microbiology, biochemistry, biotechnology and bioinformatics. The partnership promotes integration with students through Work-Integrated Learning (WIL), job shadowing and experiential education. Graduates will also have the opportunity to closely interact with Turnstones researchers to receive guidance and mentorship.

Talent development is a key objective of this exciting and mutually beneficial research partnership. Together through our partnership, Carleton University and Turnstone are preparing the next generation of life sciences researchers to continue advancing immunotherapies with the aim of improving the survival rate of people with cancer, said Rafik Goubran, PhD, Vice-President (Research and International) and Chancellors Professor, Carleton University.

About Carleton University

Carleton is a dynamic, research-intensive institution that engages in partnerships to addressthe worlds most pressing issues. The universitys corporate collaborations bring together world-class companies, researchers and a new generation of talent with 32,000 students to deliver innovations and results that are driving a more prosperous, sustainable future.

About Turnstone Biologics

Turnstone Biologics, a clinical stage biotechnology company, is developing new medicines to treat and cure solid tumours by pioneering differentiated approaches with two clinically-validated technologies, tumour infiltrating lymphocyte (TIL) therapy and viral immunotherapy. Turnstones innovative TIL therapy, which is designed to extend the efficacy of TILs to multiple solid tumour indications by selecting and manufacturing the most potent tumour-reactive T-cells (Selected TILs) for tumour eradication, represents the Companys foundational therapeutic modality driving its cancer immunotherapy pipeline. The Companys lead Selected TIL therapy candidate, TIDAL-01, is expected to enter clinical trials in 2022. Turnstone is developing additional strategies to further potentiate the clinical benefit of Selected TILs, including use in combination with their novel viral immunotherapy.

For more information, please visit http://www.turnstonebio.com, and follow Turnstone on LinkedIn.

Media ContactSteven Reid (he/him)Media Relations OfficerCarleton University613-265-6613Steven.Reid3@carleton.ca

Follow us on Twitter:www.twitter.com/CunewsroomCOVID 19 Updates:https://newsroom.carleton.ca/coronavirus-covid-19/messages/

Wednesday, August 31, 2022 in News ReleasesShare: Twitter, Facebook

See the rest here:
Carleton University and Turnstone Biologics Extend partnership for Research and Training in Biosciences - Carleton Newsroom

Nanomix Appoints Industry Veteran Tadd S. Lazarus, M.D., to the Board of Directors – Marketscreener.com

SAN LEANDRO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCQB: NNMX) (Nanomix or the Company), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced the appointment of Tadd S. Lazarus, M.D., to the Board of Directors as an independent director.

We are extremely pleased to welcome Tadd S. Lazarus, M.D., to the board and leadership of the Company, said Dr. Thomas Schlumpberger, CEO of Nanomix. His medical leadership will be of great value for commercializing the current Nanomix critical infection assay panel as well as for developing new products on the Nanomix platform, the eLab.

Dr. Lazarus brings an important medical and industry perspective to the Nanomix Board, said Garrett Gruener, Chairman of the Nanomix Board of Directors. Tadds input and counsel will be very valuable as we accelerate our commercial efforts and broaden our product portfolio.

I am thrilled about working with the Nanomix team to fully develop the exciting eLab mobile diagnostics testing platform. The Nanomix goal to improve Point of Care testing for critical conditions will meet an important and growing need in the medical community, said Tadd S. Lazarus, MD.

Dr. Lazarus has led multiple organizations as Chief Medical Officer encompassing biochemistry, medical diagnostics, and patient services arenas. Companies include Achieve Health Management, Inivata Inc., and Clinical Genomics. He served as Chief Medical Officer and Head of Medical & Scientific Affairs, Reimbursement, and Public Policy at Qiagen from 2013 through 2016. In 2010, Lazarus was at Gen-Probe Inc., (now Hologic), as Chief Medical Officer and VP of Clinical Affairs, where he was responsible for a 42-person team dedicated to clinical trials. Lazarus began his career at Roche Diagnostics, where he held simultaneous roles in private practice and as Director of Medical and Scientific Affairs, and then as the North American Medical Director for the molecular diagnostics, POC, diabetes, clinical chemistry, and immunology lines of business. Dr. Lazarus received a Bachelor of Science in Biology & Physiology from Marlboro College and earned his Medical Degree from Ross University School of Medicine.

The Nanmix eLab system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The Nanmix eLab system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. Furthermore, the S1 Panel Cartridge was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for procalcitonin (PCT), C-reactive protein (CRP) and lactate (LAC) from a single venous whole blood or plasma sample type. The assay runs on the eLab Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The S1 Panel assay has received the CE marking in Europe and has UK Medicines and Healthcare products Regulatory Agency (MHRA) registration.

About Nanomix Corporation

Nanomix (OTCQB: NNMX) is developing mobile point-of-care diagnostics with its Nanmix eLabSystem platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The companys products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, thereby enabling faster clinical decision-making and potentially treatment-in-place. Nanomixs first assays address the need for faster diagnosis of critical infections including sepsis. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes. For more information, visit http://www.nano.com.

Forward-Looking Statements

Certain statements in this press release constitute forward-looking statements within the meaning of the federal securities laws. Forward looking statements include statements regarding the Companys intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Companys ongoing and planned product development; the Companys intellectual property position; the Companys ability to develop commercial functions; expectations regarding product launch and revenue; the Companys results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled Risk Factors in the Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as well as discussions of potential risks, uncertainties, and other important factors in the Companys subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

Natalya RudmanCrescendo Communications, LLCEmail: NNMX@crescendo-ir.com Tel: (212) 671-1020 Ext.304

2022 GlobeNewswire, Inc., source Press Releases

Read this article:
Nanomix Appoints Industry Veteran Tadd S. Lazarus, M.D., to the Board of Directors - Marketscreener.com

Researchers use nitric oxide scavengers to target triple-negative breast cancer – Newswise

Newswise Researchers are exploring a potential new therapeutic approach for triple negative breast cancer treatment. Amir Abdo Alsharabasy, a CRAM doctoral candidate working in the laboratory of Professor Abhay Pandit, is working on the design of nitric oxide scavengers to form a new treatment approach for this aggressive form of breast cancer.

Triple-negative breast cancer is invasive breast cancer that does not respond to hormonal therapy medicines or the current medicines that target the HER2 protein. Triple-negative breast cancer is usually more aggressive, harder to treat, and more likely to recur than cancers that are hormone receptor-positive or HER2-positive.

Nitric oxide is one of the prominent free radicals produced by the tumor tissue, explains Amir, It, at certain concentrations, plays a significant role in breast cancer progression by inducing the cancer cells to spread to other parts of the body Our goal is to develop injectable hydrogel formulations, which can reduce the levels of, or scavenge the nitric oxide, while enhancing the generation of carbon monoxide, so that we can potentially design a new treatment approach for triple negative breast cancer.

Nitric oxide interacts with different components of the large network of proteins and other molecules that surround, support, and give structure to tumor cells and tissues in the body. Hyaluronic acid is one of the main components of this network and is the material of choice for fabricating these hydrogels.

HA plays multiple roles in tumour tissues says Amir. However, its interactions with nitric oxide have not been thoroughly investigated. The study, recently published inBiomacromolecules,attempts to understand the mechanism of these interactions and the different effects on nitric oxide levels and migration of breast cancer cells.

The study is supervised by Prof Abhay Pandit, Scientific Director of CRAM, and was published with collaborators Dr Sharon Glynn from the Lambe Institute for Translational Research and Dr Pau Farras from the School of Biological and Chemical Sciences in the Ryan Institute at the National University of Ireland Galway,

The work investigated the ability of HA to scavenge nitric oxide. The team found that the conversion of nitric oxide to certain nitrogen centred free radicals causes the HA to break down, which further inhibits the nitric oxide induced migration of cancer cells in the tumor environment.

Collectively, these results help toward understanding the involvement of HA in nitric oxide induced cell migration and suggests the potential use of modified HA, as a key material in different biomedical applications.

Commenting on the study, Professor Abhay Pandit, said: While the recent progress in research about the roles of nitric oxide with tumour progression resulted ultimately in a number of ongoing clinical trials for evaluating the effects of NO-synthase inhibitors, we are focusing on NO itself trying to avoid the side effects/reactions of these inhibitors.

Amir Abdo Alsharabasy received a BSc in Chemistry & Biochemistry, Mansoura University, Egypt, MSc in Biochemistry, Helwan University, Egypt and MSc in Biological and Bioprocess Engineering, Sheffield University, U.K. He spent some time working as a research assistant in Radiation Chemistry Department at NCRRT, Egypt. He was recently awarded two awards for his research. The first was a presentation award from the Second International Conference Therapeutic Applications of Nitric Oxide in Cancer and Inflammatory-related Diseases for his talk on the interactions between nitric oxide and hemin and their implications in the nitration of proteins in breast cancer cells. The second was an EMBO Scientific Exchange Grant to support a visit of the laboratory of Dr. Lasse Jensen in Linkping Univ., Sweden.

-ends-

More here:
Researchers use nitric oxide scavengers to target triple-negative breast cancer - Newswise

Research on the Road | The UCSB Current – The UCSB Current

Call it lucky number 10.

Six graduate students, three faculty members and one staff member from UC Santa Barbara have received Fulbright Awards from the U.S. Department of State and the Fulbright Foreign Scholarship Board to conduct research and/or teach abroad for the upcoming academic year.

The highly competitive fellowship is designed to increase mutual understanding between the people of the United States and the people of other countries.

Students are selected for Fulbright Fellowships on the basis of their academic and professional achievements, as well as their record of service and leadership potential in their respective fields.

Every year the Graduate Division, along with the Office of Undergraduate Education and faculty reviewers from across campus, support applicants to the Fulbright U.S. Student Program who seek to do research, teach or study for a year in places all over the globe, said Shawn Warner, Graduate Divisions director of professional development.We are so excited that over a third of our campus 15 applicants to the program for the upcoming year were selected as awardees. These 6 students will spend the upcoming academic year carrying out their projects in 5 different countries, all while supporting the Fulbright mission of cultural exchange and ambassadorship.

The winning fellows, their departments, projects and host countries are:

Clara Bailey, Chemistry and Biochemistry, Engineered Microbiomes for Soil Pollutant Remediation (Switzerland)

Sabra Harris, East Asian Language and Cultural Studies, Emergent Indigeneities within Public-Facing Ainu Performance (Japan)

Johanna Krukowski, Theater and Dance, Spectral Frequencies: Recovering the Lost History of Australian Horror Radio (Australia)

Jackson Stephenson, Religious Studies, The Afterlife of Indian Esoteric Buddhist Poetry (India)

Felicity Stone-Richards, Political Science, The Search for Acknowledgment: Anti-Racist and Pro-Immigration Praxis in Japan (Japan)

Kira Weiss, Music, A Contested Symbol with a Dynamic Voice: The Cello and Egyptian Cultural Policy (Egypt)

In addition, three faculty members and one UCSB staff member have received Fulbright U.S. Scholar Program awards:

Professor Paul Amar, Global Studies (Brazil) Associate Professor William Elison, Religious Studies (India)Professor Paul Leonardi, Technology Management (Austria) Regional Advisor Megan Pankratz, Education Abroad Program (Korea)

Fulbright Scholars engage in cutting-edge research and expand their professional networks, often continuing collaborations started abroad and laying the groundwork for future partnerships. Upon returning to their home countries, institutions, labs and classrooms, they share their stories and often become active supporters of international exchange, inviting foreign scholars to campus and encouraging colleagues and students to go abroad. Fulbright Scholar alumni include 61 Nobel Prize laureates, 89 Pulitzer Prize recipients, and 40 who have served as a head of state or government.

Over its 75-year history, the Fulbright Program has provided more than 400,000 participants chosen for their academic merit and leadership potential with the opportunity to exchange ideas and contribute to finding solutions to challenges facing our communities and our world. More than 800 U.S. scholars, artists and professionals from all backgrounds annually teach or conduct research overseas through the Fulbright U.S. Scholar Program. Additionally, over 1,900 diverse U.S. students, artists and early career professionals in more than 100 different fields of study receive Fulbright U.S. Student Program grants annually to study, teach English and conduct research overseas.

As the U.S. governments flagship international educational exchange program, the Fulbright Program is funded through an annual appropriation made by the U.S. Congress to the U.S. Department of States Bureau of Educational and Cultural Affairs. Participating governments and host institutions, corporations and foundations around the world also provide direct and indirect support.

In the United States, the Institute of International Education supports the implementation of the Fulbright U.S. Student and Scholar Programs on behalf of the U.S. Department of State, including conducting an annual competition for the scholarships.

Read this article:
Research on the Road | The UCSB Current - The UCSB Current

Indore: V-C cautions teachers, and staff as the impostor gets active again to dupe people – Free Press Journal

Indore (Madhya Pradesh): Nearly four months after he had succeeded in duping a professor of Rs 2.5 lakh, apparently the same conman has again got active in impersonating the DAVV vice-chancellor professor Renu Jain and is trying the same tactics to swindle people of their hard earned money.

Using Jains picture on his WhatsApp account, the conman is sending messages to the teaching and non-teaching staff on their phone numbers requestingfor financial assistance.

When the V-C came to know about this, she posted a message on social media cautioning people. Somebody from 92679 21708 is trying to chat and cheat on WhatsApp using my photo. Please be careful and don't reply to any query.This number isnt mine. Im okay and dont need any financial assistance, Jains social media post reads.

Four months ago, several teachers received a message from a WhatsApp number bearing Jains photo in the display picture. That message read that she was busy at a crucial meeting and wanted the recipient of the message to buy Amazon gift cards for her. School of Biochemistry head professor Rekha Gadre had fallen prey to the fraud. She got her daughter to buy Amazon gift cards worth Rs 2.5 lakh for the V-C and gave them to the impostor. An FIR was registered in the matter, but the conman was never arrested. He, perhaps, has got active again and is using the same tactics to cheat the university staff.

(To receive our E-paper on whatsapp daily, please click here.To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

View original post here:
Indore: V-C cautions teachers, and staff as the impostor gets active again to dupe people - Free Press Journal

Taiwanese bring the sizzle to Rwanda –

How a family brought beef noodles, soup dumplings and other local delectables to Kigali

Anyone walking around BK Arena in the Rwandan capital of Kigali who is familar with Taiwanese cuisine might be surprised to smell the fragrance of familiar dishes in the air.

Visitors can even detect the aroma of Taiwans famous beef noodles, chive buns and dumplings if they visit the neighborhood on the right day.

These delectable flavors can be traced to Sizzling Plates Restaurant, a small diner located just across from BK Arena.

Patrons of the eatery have a plethora of traditional Taiwanese food from which to choose, whether it is vegetarian appetizers such as braised tofu or spicy entrees like mapo tofu, or the nations staple braised pork rice and potstickers.

The restaurant also offers special deals on dumpling dishes on Thursdays and Sundays, while a phone call to the eatery a few days ahead of a visit gives owner Teresa Fang () enough time to prepare her signature soup dumplings, which are only available by request.

Besides juggling her duties as the restaurants owner and head chef, Fang, 36, is also a busy mother whose Japanese husband works for the UN in Africa.

STABLER AND SAFER

The family has traveled across Africa due to her husbands job, but the couple eventually decided to settle down in Rwanda, where both parents can work while their children grow up in an environment that is stabler and safer than neighboring nations, Fang said.

With degrees in health economics and biochemistry, plus previous work experience as a researcher and tutor at graduate school, Fang originally planned to look for a job within her field of expertise.

However, with the outbreak of the COVID-19 pandemic, Fang was forced to seek alternative job solutions when the companies she had set her heart on stopped hiring.

That was when the chance of purchasing a restaurant across the street from East Africas biggest indoor arena presented itself. Only then did Fang decide to make a hard turn in her career path and pursue cooking full time.

She recalled how she enjoyed recreating the flavors of her hometown cuisine while attending high school abroad, and the excitement she felt when she made dumpings for her and her husband while they lived in Australia. When they had children, she also felt happy making healthy food for them.

Fang was also motivated by her father, who passed away in February 2020.

I reflected on the time we had together and how he truly lived in accordance with the love what you do and you will never work a day in your life philosophy, Fang said. He truly enjoyed his work and always encouraged us to do what makes us happy and healthy.

Sizzling Plates opened its doors in early 2020 amid the global pandemic, which Fang attributes to her personality of needing to get things done.

The restaurant first tailored to the expat population looking to satisfy their desire for something different from the ubiquitous Rwandan cuisine. Eventually, the dishes became popular, customers kept coming back with friends and word spread.

In the two years since the restaurant opened, Fang said she has even served six or seven fellow Taiwanese nationals.

LOCAL AND NATURAL

Instead of Taiwanese ingredients, Fang bases her recipes on local products and draws from her background as a health economics expert.

I have always been very health conscious with my background in biochemistry, and of course after I become a mom, Fang said. I tend to use natural ingredients to make food for my family. After moving to Rwanda, I have to cook almost everything from scratch because its not easy to find Asian condiments.

Not only does she insist on using no MSG in her food, Fang also makes sure no artificial flavoring is added to the Rwandan soybeans which she uses to make homemade tofu for her eatery.

Fang also taught her employees how to use a dough roller to turn Rwandas wheat flour into Taiwanese buns and dumplings.

Thanks to her insistence on using healthy ingredients and the unique flavors of Taiwanese cuisine, Sizzling Plates currently has an exclusive menu that sets her food apart from other Asian restaurants in the area.

When asked about the challenges in Rwanda, Fang points to the language and cultural differences she faces everyday, such as the pace of daily life and managing a restaurant in a country that has an unstable power grid and water supply.

That aside, Fang said she and her family are content and happy in the African country and will continue to bring the sizzle to Kigali.

I really enjoy raising my kids here. she said. I cherish its natural environment and the simplicity which is so rare in other countries. My kids also enjoy living here. I dont know where life is going to take us, but for now we are just enjoying ourselves here.

Comments will be moderated. Keep comments relevant to the article. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned. Final decision will be at the discretion of the Taipei Times.

Continue reading here:
Taiwanese bring the sizzle to Rwanda -

"Blue Pea Flower and Banana Stem Extract" Drink to Reduce the Risk of Urinary Stone – Another Medical Innovation from Chula MED – PR…

BANGKOK, Sept. 1, 2022 /PRNewswire/ -- Urinary tract stone is common among people of the tropics such as Thailand. In 2020, surveys show that 16-17 percent of the population have this disease, and up to 12 percent of the patients have an asymptomatic urinary stone.

HydroZitla - Blue Pea Flower and Banana Stem Extract Drink to Reduce the Risk of Urinary Stone

"People with the early urinary stone disease are often unaware of it and its life-threatening danger, so they neglect to prevent it. But when the stones are larger, they cause urinary obstructions, pain, difficulty urinating, and blood in the urine in some people. The problem with urinary stone is its recurrence, and that can lead to chronic kidney failure," said Asst. Prof. Dr. Chanchai Boonla, Department of Biochemistry, Chula Faculty of Medicine. The most commonly known treatments are medications, shock wave lithotripsy SWL), and surgery.

Recently, Chula MED launched the latest tasty and nutritious medical innovation that can prevent urinary stone formation HydroZitLa a concentrated herbal drink with "blue pea flower" and "banana stem" by a team of researchers comprising Asst. Prof. Dr. Chanchai Boonla, Asst. Prof. Dr. Nattida Chotechuang, Mr. Bundit Prachapiban, Ms. Natcha Madared, and a number of master's and doctoral degree students.

"Not drinking enough waterand eating foods and vegetables high in oxalate, such as betel leaves can lead to urinary stones." Also, low secretion of urinary citrateand high oxidative stresscandestroy kidney cells and attract the crystallization of the urinary stones. Moreover, consuming food high in sodium and protein also increases the chance of urinary stone formation.

"The urinary stone inhibitor is citrate, which is found in citrus fruits, such as lemon, grapefruit, bergamot, tart cranberries, and melons, which Thai people tend not to prefer as much as sweet fruits, making it easy for the body to get less citrate. Antioxidants are found in fruits and vegetables.

HydroZitla Citrate Plus drink is a combination of modern and traditional medicine.Banana stemshave a diuretic effect and can reduce the amount of oxalate in the urine. Blue pea flowersare high in antioxidants and give out a beautiful natural color.

Having been certified by the Food and Drug Administration (FDA), HydroZitLa is currently available at the vending machines selling Chula medical innovations or Facebookpage: https://www.facebook.com/HydroZitLa

For more information, visithttps://www.chula.ac.th/en/highlight/48548/

The rest is here:
"Blue Pea Flower and Banana Stem Extract" Drink to Reduce the Risk of Urinary Stone - Another Medical Innovation from Chula MED - PR...

UCSF Department of Biochemistry & Biophysics

The Stein and Moore Award, named for Nobel laureates Dr. William Stein and Dr. Stanford Moore, venerates their contribution to understanding the connection between chemical structure and catalytic activity of the active center of the ribonuclease molecule. Established in 1986, the Stein and Moore Award is given to recognize eminent leaders in protein science who have made sustained high impact research contributions to the field.

More...

View original post here:
UCSF Department of Biochemistry & Biophysics